Long-term outcome and efficacy of cyclophosphamide therapy in Japanese patients with ANCA-associated microscopic polyangiitis: A retrospective study

Internal Medicine

Volumn 52, Issue 22, 2013, Pages 2503-2509

  Nakaya, Izaya ^a   Yahata, Mayumi ^a   Takahashi, Satoko ^a   Sasajima, Tomomi ^a   Sakuma, Tsutomu ^a   Shibagaki, Yugo ^b   Soma, Jun ^a  

^a Iwate Prefectural Central Hospital   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE HOSPITAL   (Japan)

Author keywords

Anti neutrophil cytoplasmic antibody; Birmingham vasculitis activity score; Cyclophosphamide; Microscopic polyangiitis; Remission induction

Indexed keywords

C REACTIVE PROTEIN; COTRIMOXAZOLE; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHOTREXATE; METHYLPREDNISOLONE; MIZORIBINE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; SERUM ALBUMIN;

AGED; ARTICLE; BONE MARROW SUPPRESSION; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MICROSCOPIC POLYANGIITIS; MORTALITY; PNEUMOCYSTIS PNEUMONIA; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ASIAN CONTINENTAL ANCESTRY GROUP; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; JAPAN; MALE; METHYLPREDNISOLONE; MICROSCOPIC POLYANGIITIS; MIDDLE AGED; PREDNISOLONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84887586810     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.52.0199     Document Type: Article

References (25)

1. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65: 1-11, 2013.
2. Fujimoto S, Uezono S, Hisanaga S, et al. Incidence of ANCA-associated primary renal vasculitis in the Miyazaki Prefecture: the first population-based, retrospective, epidemiologic survey in Japan. Clin J Am Soc Nephrol 1: 1016-1022, 2006.
3. Watts RA, Scott DG, Jayne DR, et al. Renal vasculitis in Japan and the UK--are there differences in epidemiology and clinical phenotype? Nephrol Dial Transplant 23: 3928-3931, 2008.
4. Fujimoto S, Watts RA, Kobayashi S, et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vas-culitis between Japan and the U.K. Rheumatology (Oxford) 50: 1916-1920, 2011.
5. Fauci AS, Katz P, Haynes BF, Wolff SM. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 301: 235-238, 1979.
6. de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cy-clophosphamide for induction of remission in antineutrophil cyto-plasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 150: 670-680, 2009.
7. Harper L, Morgan MD, Walsh M, et al. Pulse versus daily oral cy-clophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 71: 955-960, 2012.
8. Koyama A, Yamagata K, Makino H, et al. A nationwide survey of rapidly progressive glomerulonephritis in Japan: etiology, prognosis and treatment diversity. Clin Exp Nephrol 13: 633-650, 2009.
9. Guidelines for the treatment of rapidly progressive glomeru-lonephritis, second version. Nihon Jinzo Gakkai Shi 53: 509-555, 2011 (Abstract in English).
10. Ethical Guidelines for Epidemological Research. 2002 (Accessed at http://www.niph.go.jp/wadai/ekigakurinri/guidelines.pdf).
11. Ozaki S. ANCA-associated vasculitis: diagnostic and therapeutic strategy. Allergol Int 56: 87-96, 2007.
12. Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 87: 671-678, 1994.
13. Flossmann O, Bacon P, de Groot K, et al. Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis 66: 283-292, 2007.
14. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982-992, 2009.
15. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68: 310-317, 2009.
16. Adu D, Pall A, Luqmani RA, et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM 90: 401-409, 1997.
17. de Groot K, Adu D, Savage CO; Euvas. The value of pulse cyclo-phosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 16: 2018-2027, 2001.
18. Hogan SL, Nachman PH, Wilkman AS, Jennette JC, Falk RJ. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomeru-lonephritis. J Am Soc Nephrol 7: 23-32, 1996.
19. Ozaki S, Atsumi T, Hayashi T, et al. Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study. Mod Rheumatol 22: 394-404, 2012.
20. Turnbull J, Harper L. Adverse effects of therapy for ANCA-associated vasculitis. Best Pract Res Clin Rheumatol 23: 391-401, 2009.
21. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclo-phosphamide for ANCA-associated vasculitis. N Engl J Med 363: 221-232, 2010.
22. Jones RB, Cohen Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363: 211-220, 2010.
23. Silva F, Specks U, Kalra S, et al. Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement--a prospective, open-label pilot trial. Clin J Am Soc Nephrol 5: 445-453, 2010.
24. Hu W, Liu C, Xie H, Chen H, Liu Z, Li L. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant 23: 1307-1312, 2008.
25. Jayne DR, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18: 2180-2188, 2007.